FiercePharma  May 25  Comment 
It’s taken five months, but the FDA has finally issued its first untitled letter of the year for promotional infractions. The agency's watchdogs scolded Orexigen Therapeutics for infractions in a TV commercial for weight loss drug Contrave.
Benzinga  May 2  Comment 
Meet Orexigen Therapeutics, Inc. (NASDAQ: OREX), a micro-cap biopharmaceutical company delivering one of the strongest stock market performances of 2017 so far. After losing almost 90 percent of its value over 2016, shares have recuperated more...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki